Whether serum CEACAM5 fluctuations reflect EMT and rEMT in primary tumors and metastatic sites to enable cancer cell dissemination and proliferation under EGFR‐TKI treatment and latter drug resistance requires further investigation. This evidence concerns the gene EGFR and cancer.